We now show that simultaneous inhibition of both MCL1 (with S63845) and BCL-2 (with venetoclax or S55746) is highly synergistic in AML and extends low nanomolar activity with the combination to approximately half the primary AML samples tested, spanning a broad spectrum of cytogenetic and molecular profiles. Here, BCL2 is linked to acute myeloid leukemia.